Xilingio M 25mg/5mg/1000mg Tablet ER

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin.

Xilingio M is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to any component. Caution is advised in patients at risk of volume depletion or urinary tract infections. Regular monitoring of renal function, glycemic control, and potential adverse effects is recommended during therapy. This combination therapy offers a comprehensive approach to glycemic control by targeting multiple pathophysiological mechanisms of type 2 diabetes.